In the latest trading session, 0.45 million Sagimet Biosciences Inc (NASDAQ:SGMT) shares changed hands as the company’s beta touched 2.34. With the company’s most recent per share price at $4.55 changed hands at -$0.63 or -12.07% at last look, the market valuation stands at $139.73M. SGMT’s current price is a discount, trading about -355.16% off its 52-week high of $20.71. The share price had its 52-week low at $2.39, which suggests the last value was 47.47% up since then. When we look at Sagimet Biosciences Inc’s average trading volume, we note the 10-day average is 1.67 million shares, with the 3-month average coming to 906.58K.
Analysts gave the Sagimet Biosciences Inc (SGMT) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.25. If we narrow down to specifics, the data shows that 0 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended SGMT as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. Sagimet Biosciences Inc’s EPS for the current quarter is expected to be -0.63.
Sagimet Biosciences Inc (NASDAQ:SGMT) trade information
Instantly SGMT was in red as seen in intraday trades today. With action -8.35%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 1.22%, with the 5-day performance at -8.35% in the red. However, in the 30-day time frame, Sagimet Biosciences Inc (NASDAQ:SGMT) is -6.85% down. Looking at the short shares, we see there were 4.17 million shares sold at short interest cover period of 1.37 days.
The consensus price target for the stock as assigned by Wall Street analysts is 6, meaning bulls need an upside of 24.17% from its recent market value. According to analyst projections, SGMT’s forecast low is 6 with 6 as the target high. To hit the forecast high, the stock’s price needs a -31.87% plunge from its current level, while the stock would need to soar -31.87% for it to hit the projected low.
Sagimet Biosciences Inc (SGMT) estimates and forecasts
Data shows that the Sagimet Biosciences Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 36.79% over the past 6 months, a 39.47% in annual growth rate that is considerably higher than the industry average of 16.40%. Year-over-year growth is forecast to reach -100.00% down from the last financial year.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -16.23%. The 2025 estimates are for Sagimet Biosciences Inc earnings to increase by 44.34%.
SGMT Dividends
Sagimet Biosciences Inc is expected to release its next quarterly earnings report in February.
Sagimet Biosciences Inc (NASDAQ:SGMT)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 14.11% of Sagimet Biosciences Inc shares while 66.94% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 77.94%.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and BlackRock Health Sciences Term Trust. With 763.99 shares estimated at $3.46 million under it, the former controlled 2.49% of total outstanding shares. On the other hand, BlackRock Health Sciences Term Trust held about 1.33% of the shares, roughly 408.12 shares worth around $1.85 million.
